Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells

Science Translational Medicine

Volumn 3, Issue 80, 2011, Pages

  Butler, Marcus O ^a,b,c   Friedlander, Philip ^a,b,c   Milstein, Matthew I ^a   Mooney, Mary M ^a   Metzler, Genita ^a   Murray, Andrew P ^a   Tanaka, Makito ^a,b,c   Berezovskaya, Alla ^a   Imataki, Osamu ^a,b,c   Drury, Linda ^a   Brennan, Lisa ^a   Flavin, Marisa ^a   Neuberg, Donna ^a   Stevenson, Kristen ^a   Lawrence, Donald ^b,c   Hodi, F Stephen ^a,b,c   Velazquez, Elsa F ^b,d   Jaklitsch, Michael T ^c,e   Russell, Sara E ^b,c   Mihm, Martin ^a,b,c   Nadler, Lee M ^a,b,c   Hirano, Naoto ^a,b,c,f,g   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPLATIN; GLYCOPROTEIN GP 100 VACCINE; INTERFERON; IPILIMUMAB; MELAN A; MELPHALAN; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; EPITOPE; INTERLEUKIN 15; INTERLEUKIN 2; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; ENGRAFTMENT; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; CELL MOTION; CLINICAL TRIAL; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MIDDLE AGED; TIME; TRANSPLANTATION;

ADOPTIVE TRANSFER; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; EPITOPES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; INTERLEUKIN-15; INTERLEUKIN-2; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 79955373860     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002207     Document Type: Article

References (36)

1. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
2. M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White, S. A. Rosenberg, Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
3. C. Berger, C. J. Turtle, M. C. Jensen, S. R. Riddell, Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr. Opin. Immunol. 21, 224-232 (2009).
4. S. A. Rosenberg, M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
5. M. K. Brenner, H. E. Heslop, Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 22, 251-257 (2010).
6. C. M. Paulos, M. M. Suhoski, G. Plesa, T. Jiang, S. Basu, T. N. Golovina, S. Jiang, N. A. Aqui, D. J. Powell Jr., B. L. Levine, R. G. Carroll, J. L. Riley, C. H. June, Adoptive immunotherapy: Good habits instilled at youth have long-term benefits. Immunol. Res. 42, 182-196 (2008).
7. T. M. Schmitt, G. B. Ragnarsson, P. D. Greenberg, T cell receptor gene therapy for cancer. Hum. Gene Ther. 20, 1240-1248 (2009).
8. C. Yee, Adoptive therapy using antigen-specific T-cell clones. Cancer J. 16, 367-373 (2010).
9. M. E. Dudley, J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, S. F. Leitman, S. A. Rosenberg, Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373 (2001).
10. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16168-16173 (2002).
11. M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, J. Kan-Mitchell, Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20, 1075-1086 (2002).
12. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24, 5060-5069 (2006).
13. P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell Jr., S. A. Rosenberg, Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130 (2004).
14. J. Zhou, M. E. Dudley, S. A. Rosenberg, P. F. Robbins, Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28, 53-62 (2005).
15. J. Zhou, X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg, P. F. Robbins, Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (2005).
16. S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, D. E. White, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166 (1994).
17. C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, P. D. Greenberg, Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644 (2000).
18. H. Wallen, J. A. Thompson, J. Z. Reilly, R. M. Rodmyre, J. Cao, C. Yee, Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4, e4749 (2009).
19. + cells. J. Exp. Med. 195, 1523-1532 (2002).
20. + T cells. J. Exp. Med. 202, 907-912 (2005).
21. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601 (2005).
22. + T cells and preferential enrichment for antigen specificity. Blood 107, 1528-1536 (2006).
23. + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13, 1857-1867 (2007).
24. + T cells in a large proportion of human histocompatibility leukocyte antigen (Hla)-A2 individuals. J. Exp. Med. 190, 705-715 (1999).
25. J. D. Wolchok, A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbé, M. Maio, M. Binder, O. Bohnsack, G. Nichol, R. Humphrey, F. S. Hodi, Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
26. + T cell longevity in vivo. J. Immunol. 179, 4550-4562 (2007).
27. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9571-9576 (2005).
28. + T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 5201-5206 (2008).
29. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
30. J. Weber, Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 58, 823-830 (2009).
31. L. Fong, E. J. Small, Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275-5283 (2008).
32. S. S. Agarwala, A. Ribas, Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J. Immunother. 33, 557-569 (2010).
33. J. E. Coligan, B. E. Bierer, D. H. Margulies, E. M. Shevach, W. Strober, R. Coico, Current Protocols in Immunology (Wiley, New York, 2010).
34. M. C. Mihm Jr., C. G. Clemente, N. Cascinelli, Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74, 43-47 (1996).
35. R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, J. Lukanich, R. Bueno, J. Wain, D. Mathisen, C. Wright, P. Fidias, D. Donahue, S. Clift, S. Hardy, D. Neuberg, R. Mulligan, I. Webb, D. Sugarbaker, M. Mihm, G. Dranoff, Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
36. Acknowledgments: We thank the Dana-Farber Cancer Institute Connell-O'Reilly Cell Manipulation Core Facility for the generation of CTL grafts. We thank J. Daley and S. Lazo-Kallanian at the flow cytometry core for expert technical assistance, and S. Conley for photography. Funding: Funding was provided by the Immunotherapy Fund 1 (L.M.N.), the S. Craig Lindner Fund for Cancer Research (L.M.N.), the Rudolf E. Rupert Foundation for Cancer Research (L.M.N.), the Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative (M.O.B., L.M.N., and N.H.), Friends of the Dana-Farber Cancer Institute (M.O.B. and N.H.), and Dunkin' Donuts Rising Stars Program (M.O.B. and N.H.). N.H. was funded by NIH grants K22CA129240 and R01CA148673 and the American Society of Hematology Scholar Award. Preclinical scale-up was supported by the Center for Human Cell Therapy Boston (NIH 5U24HL074355). Subjects received ipilimumab on clinical trials supported by Bristol-Myers Squibb (F.S.H.). Author contributions: M.O.B., N.H., and L.M.N. conceived the study and wrote the paper. M.O.B. performed the clinical trial as the principal investigator. P.F., L.D., L.B., M.F., D.L., F.S.H., M.T.J., and S.E.R. assisted with conducting the clinical trial. D.N. and K.S. performed statistical analysis. M.O.B. and N.H. designed and conducted laboratory experiments. M.I.M., M.M.M., G.M., M.T., A.P.M., A.B., and O.I. helped to perform experiments. E.F.V. and M.M. analyzed histopathological specimens. All authors approved the manuscript. Competing interests: The Dana-Farber has filed a patent related to aAPC, application number 10/850,294, entitled "Modified Antigen-Presenting Cells," on which M.O.B., L.M.N., and N.H. are named as inventors. F.S.H. is a nonpaid consultant to Bristol-Myers Squibb. The other authors declare that they have no competing interests.